Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

Clinical Infectious Diseases

Volumn 28, Issue 3, 1999, Pages 419-430

  Burman, William J ^a,b   Gallicano, Keith ^a,b   Peloquin, Charles ^a,b  

^a DENVER PUBLIC HEALTH   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMPRENAVIR; ANTIRETROVIRUS AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; ETHIONAMIDE; INDINAVIR; ISONIAZID; LEVOFLOXACIN; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ZIDOVUDINE;

ARTICLE; DRUG ABSORPTION; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; FOOD DRUG INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 0033012497     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515174     Document Type: Article

References (108)

1. 1. Gulik RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337: 734-9.
2. 2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
3. 3. CAESER Coordinating Committee. Randomized trial of addition of lamivudine or lamivudine plus lovaride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349:1413-21.
4. 4. Palella F Jr, Delany K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
5. 5. Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampicin and isoniazid. N Engl J Med 1984;311:1681-3.
6. 6. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994;18:266.
7. 7. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74.
8. 8. D'Arcy PF, McElnay JC, Welling PG. Mechanisms of drug interactions. Berlin: Springer-Verlag, 1996.
9. 9. Rolan PE. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37:125-8.
10. 10. MacKichan JJ. Protein binding drug displacement interactions fact or fiction? Clin Pharmacokinet 1989;16:65-73.
11. 11. Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 1996;30:445-62.
12. 12. Li AP, Reith MK, Rasmussen A, et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine, and rifabutin. Chem Biol Interact 1997;107:17-30.
13. 13. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome p450 isoforms by the protease inhibitors, ritonavir, saquinavir, and indinavir. Br J Clin Pharmacol 1997;44:190-4.
14. 14. von Moltke LL, Greenblatt DJ, Grassi BW, et al. Protease inhibitors as inhibitors of human cytochrome P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-11.
15. 15. Woolley J, Studenberg S, Boehlert C, Bowers G, Sinhababu A, Adams P. Cytochrome p-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94 [abstract no A-60]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:12.
16. 16. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998;87: 803-7.
17. 17. Cato A, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman GR. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998;63:414-21.
18. 18. Ouellet D, Hsu A, Qian J, Locke CS, Cavanaugh J. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46:111-6.
19. 19. Kerr B, Lee C, Yuen G, et al. Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate, a new HIV-1 protease inhibitor [abstract no 373]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: Foundation for Retrovirology and Human Health, 1997:133.
20. 20. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
21. 21. Gallicano K, Sahai J, Foster B, Bouchard J, Cameron DW. Rifampin decreases zidovudine plasma concentrations in HIV infected patients [abstract no 612]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: Foundation for Retrovirology and Human Health, 1997:177.
22. 22. O'Brien LW. Interactions and toxicities of drugs for HIV disease. The AIDS Reader 1998;8:28-36.
23. 23. Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Ann Pharmacother 1997;31:145-58.
24. 24. Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991;114:755-7.
25. 25. Andreana A, Aggarwal S, Gollapudi S, Wien D, Tsuruo T, Gupta S. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDRI gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type I infection. AIDS Res Hum Retrovirus 1996;12:1457-62.
26. 26. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-94.
27. 27. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates for P-glycoprotein and cytochrome P450A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49: 311-8.
28. 28. Lee BL, Wong D, Benowitz ML, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993;53:529-35.
29. 29. O'Neil WM, Gilfix BM, DiGirolamo A, Tsoukas CM, Wainer IW. N-Acetylation among HIV positive and AIDS patients: when is fast, fast and slow, slow? Clin Pharmacol Ther 1997;62:261-71.
30. 30. Kaufmann GR, Wenk M, Taeschner W, et al. N-Acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1996;60:62-7.
31. 31. Acocella G, Nonis A, Perna G, Patane E, Gialdroni-Grassi G, Grassi C. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. Am Rev Respir Dis 1988;138:886-90.
32. 32. Ellard GA, Ellard DR, Allen BW, et al. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am Rev Respir Dis 1986;133:1076-80.
33. 33. Larsson LO, Berning SE, Peloquin CA. Is monitoring of drug therapy in patients with cystic fibrosis and mycobacterial disease necessary? [abstract]. Am J Respir Crit Care Med 1997;155:A642.
34. 34. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculous drugs in patients with HIV infection. Ann Intern Med 1997;127:289-93.
35. 35. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996;30: 919-25.
36. 36. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculosis medications by a patient with AIDS [letter]. N Engl J Med 1992;327:1817-8.
37. 37. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients [letter]. N Engl J Med 1995;332: 336-7.
38. 38. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications [letter]. N Engl J Med 1993;329:1122-3.
39. 39. Gordon SM, Horsburgh CR Jr, Peloquin CA, et al. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis 1993;168:1559-62.
40. 40. Colborn D, Lewis R, Narang P. HIV disease severity does not influence rifabutin absorption [abstract no A-42]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 1994:39.
41. 41. Gatti G, Papa P, Torre D, et al. Population pharmacokinetic analysis of rifabutin in HIV-infected patients [abstract no A-10]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:2.
42. 42. Owens RC Jr, Keung AC, Gardner S, et al. Pharmacokinetic and food effect evaluation of rifapentine in subjects seropositive for the human immunodeficiency virus [abstract no A-2]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:1.
43. 43. Owens RC, Pate KB, Benevicius MA, Quintiliani R, Nightingale CH, Nicolau DP. Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. Antimicrob Agents Chemother 1997;41: 1508-11.
44. 44. Ehrenpreis ED, Ganger DR, Kochvar GT, Patterson BK, Craig RM. Dxylose malabsorption: characteristic finding in patients with the AIDS wasting syndrome and chronic diarrhea. J Acquir Immune Defic Syndr 1992;5:1047-50.
45. 45. Kotler DP, Francisco A, Clayton F, Scholes JV, Orenstein JM. Small intestinal injury and parasitic diseases in AIDS. Ann Intern Med 1990; 113:444-9.
46. 46. Kotler DP, Giang TT, Thiim M, Nataro JP, Sordillo EM, Orenstein JM. Chronic bacterial enteropathy in patients with AIDS. J Infect Dis 1995; 171:552-8.
47. 47. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997;18:79-87.
48. 48. El-Sadr W, Perlman DC, Matts JP, et al. The evaluation of an intensive intermittent induction regimen and short course duration of treatment for HIV-related pulmonary tuberculosis. Clin Infect Dis 1998;26: 1148-58.
49. 49. Peloquin CA, Henshaw TL, Huitt GA, Berning SE, Nitta AT, James GT. Pharmacokinetic evaluation of p-aminosalicylic acid granules. Pharmacotherapy 1994;14:40-6.
50. 50. Lederberger B, Bettex JD, Joos B, Flepp M, Luthy R. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother 1985;27:350-2.
51. 51. Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N, Garber G. Cations in didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993;53:292-7.
52. 52. Polk RE, Healy DP, Sahai J, Drwal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989;33:1841-4.
53. 53. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Nix DE. Effect of food and antacids on the pharmacokinetics (PK) of ethambutol (EMB) and pyrazinamide (PZA) [abstract no A-3]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997:1.
54. 54. Ameer B, Polk RE, Kline BJ, Grisafe JP. Effect of food on ethambutol absorption. Clin Pharmacy 1982;1:156-8.
55. 55. Mattila MJ, Linnoila M, Seppala T, Koskinen R. Effect of aluminum hydroxide and glycopyrronium on the absorption of ethambutol and alcohol in man. Br J Clin Pharmacol 1978;5:161-6.
56. 56. Peloquin CA, Namdar R, Nix DE. Effect of food and antacids on the pharmacokinetics (PK) on isoniazid (INH) and rifampin (RIF) [abstract]. Am J Resp Crit Care Med 1998;157:A493.
57. 57. Melander A, Danielson K, Hanson A, et al. Reduction of isoniazid bioavailability in normal men by concomitant intake of food. Acta Med Scand 1976;200:93-7.
58. 58. Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid, and pyrazinamide. Tubercle Lung Dis 1995;76:109-13.
59. 59. Gallicano K, Sahai J, Zaror-Behrens G, Pakuts A. Effect of antacids in didanosine tablet on bioavailability of isoniazid. Antimicrob Agents Chemother 1994;38:894-7.
60. 60. Hurwitz A, Schlozman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rats and man. Am Rev Respir Dis 1974;109: 41-7.
61. 61. Mannisto P, Mantyla R, Klinge E, Nykanen S, Koponen A, Lamminsivu U. Influence of various diets on the bioavailability of isoniazid. J Antimicrob Chemother 1982;10:427-34.
62. 62. Lehto P, Kivisto KT. Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother 1994;38:248-51.
63. 63. Lehto P, Kivisto KT, Neuvonen PJ. The effect of ferrous sulfate on the absorption of norfloxacin, ciprofloxacin, and ofloxacin. Br J Clin Pharmacol 1994;37:82-5.
64. 64. Narang PK, Lewis RC, Bianchine JR. Rifabutin absorption in humans: relative bioavailability and food effect. Clin Pharmacol Ther 1992;52: 335-41.
65. 65. Sahai J, Narang PK, Hawley-Foss N, Li RC, Kamal M, Cameron DW. A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients. J Acquir Immun Defic Syndr 1995;9: 274-9.
66. 66. Siegler DI, Bryant M, Burley DM, Citron KM, Standen SM. Effect of meals on rifampicin absorption. Lancet 1974;2:197-8.
67. 67. Purohit SD, Johri SC, Mehta YR, Bhatnagar M. Ranitidine-rifampin interaction. J Assoc Physicians India 1992;40:308-10.
68. 68. Khalil SAH, El-Khordagui LK, El-Gholmy Z. Effect of antacids on oral absorption of rifampin. International Journal of Pharmaceutics 1984; 20:99-106.
69. 69. Rao KVN, Kailisam S, Menon NK, Radharrishna S. Inactivation of isoniazid by condensation in a syrup preparation. Indian Journal of Medical Research 1971;50:1343-53.
70. 70. Lee BL, Tauber MG, Chambers HF, Gambertoglio J, Delahunty T. The effect of zalcitabine on the pharmacokinetics of isoniazid in HIV-infected patients [abstract no A4]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1994:3.
71. 71. Chan SL, Yew WW, Porter JHD, et al. Comparison of Chinese and Western rifapentines and improvement by prior taking of various meals. Int J Antimicrob Agents 1994;3:267-74.
72. 72. Perucca E, Grimaldi R, Frigo GM, Sardi A, Monig H, Ohnhaus EE. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988;34: 595-9.
73. 73. Durand DV, Hampden C, Boobis AR, Park BK, Davies DS. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. Br J Clin Pharmacol 1986;21: 1-7.
74. 74. Indinavir pharmacokinetics study group. Indinavir (MK 639) drug interactions studies [abstract no MoB174]. In: Program and abstracts of the XI International AIDS Conference. Vancouver: XI International Conference on AIDS Society, 1996:18.
75. 75. Sahai J, Stewart F, Swick L, et al. Rifabutin reduces saquinavir plasma levels in HIV-infected patients [abstract no A27]. In: Program and abstracts of the 36th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996:6.
76. 76. Polk RE, Israel DS, Patron R, et al. Pharmacokinetic interaction between 141W94 and rifabutin and rifampin after multiple dose administration [abstract no 340]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:143.
77. 77. Product insert: Norvir. Abbott Laboratories, 1997.
78. 78. Sadler B, Gillotin C, Chittick GE, Symonds WT. Pharmacokinetic drug interactions with amprenavir [abstract no 12389]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multime-dia, 1998:91.
79. 79. Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 1997;61:544-53.
80. 80. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996;10:485-92.
81. 81. Zhang K, Wu E, Patick A, et al. Plasma metabolites of nelfinavir, a potent HIV protease inhibitor in HIV-positive patients: quantitation by LC-MS/MS and antiviral activities [abstract no 128]. Presented at the 6th European International Society for Study of Xenobiotics Meeting (Gottenberg, Sweden). 1997.
82. 82. Iatsimirskaia E, Tulebaev S, Storozhuk E, et al. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 1997;61:554-62.
83. 83. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-27.
84. 84. Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events [abstract no MoB171]. In: Programs and abstracts of the XI International Conference on AIDS. Vancouver: XI International Conference on AIDS Society, 1996:18.
85. 85. Torseth J, Bhatia G, Harkonen S, et al. Evaluation of the antiviral effect of rifabutin in AIDS-related complex. J Infect Dis 1989;159:1115-8.
86. 86. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium lung disease. Clin Infect Dis 1995;21:594-8.
87. 87. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996;335: 377-83.
88. 88. Benson CA. Critical drug interactions with agents used for prophylaxis and treatment of Mycobacterium avium complex infection. Am J Med 1997;102:32-6.
89. 89. Stretcher BN, Pesce AJ, Frame PT, Greenberg KA, Stein DS. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 1994;8:763-9.
90. 90. Barry MG, Khoo SH, Veal GJ, et al. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 1996; 10:1361-7.
91. 91. Stretcher BN, Pesce AJ, Frame PT, Stein DS. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;38:1541-7.
92. 92. Haumont M, Magdalou J, Lafaurie C, Ziegler JM, Siest G, Colin JN. Phenobarbital inducible UDP-glucuronosyltransferase is responsible for glucuronidation of 3′-azido-3′-deoxythymidine: characterization of the enzyme in human and rat liver microsomes. Arch Biochem Biophys 1990;281:264-70.
93. 93. Oesch F, Arand M, Strolin-Bendetti M, Castelli MG, Dostert P. Inducing properties of rifampin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother 1996;37:1111-9.
94. 94. Cato A, Qian J, Hsu A, Levy B, Leonard J, Granneman R. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998; 42:1788-93.
95. 95. Gallicano K, Sahai J, Swick L, Seguin I, Pakuts A, Cameron DW. Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21: 1008-11.
96. 96. Narang P, Sale M. Population-based assessment of rifabutin effect on zidovudine disposition in AIDS patients. Clin Pharmacol Ther 1993; 53:219.
97. 97. Ravitch JR, Bryant BJ, Reese MJ, et al. In vivo and in vitro studies of the potential for drug interactions involving the anti-retroviral 1592 in humans [abstract no 634]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:199.
98. 98. Product insert: Viramune. Roxane Laboratories, 1997.
99. 99. Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res 1997;35:53-63.
100. 100. Cox SR, Herman BD, Batta DH, Carel BJ, Carberry PA. Delavirdine and rifabutin: pharmacokinetic evaluation in HIV-1 patients with concentration-targeting of delavirdine [abstract no 344]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:144.
101. 101. Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers [abstract no 42280]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998:829.
102. 102. Benedeck IH, Fiske WD, White SJ, Stevenson D, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between multiple doses of efavirenz and rifabutin in healthy volunteers [abstract]. Clin Infect Dis 1998;27:1008.
103. 103. Jenner PJ, Ellard GA. High performance liquid Chromatographic determination of ethionamide and prothionamide in body fluids. Journal of Chromatography-Biomedical Applications 1981;225:245-51.
104. 104. Mannheimer SB, Medard F, El-Sadr W. The use of protease inhibitors in persons with HIV and tuberculosis [abstract]. Am J Resp Crit Care Med 1998;157:A573.
105. 105. Gazzard B, Moyle G, the BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998;352:314-6.
106. 106. Morris L, Martin DJ, Sacks L, et al. Persistent elevation of HIV viral load during therapy for tuberculosis [abstract no 259]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 1998:85.
107. 107. Raboud J, Montaner JSG, Rae S, et al. Patients with higher baseline pVL are less likely to have a virologic response in a meta-analysis of two trials of ZDV/ddI vs. ZDV/ddI/NVP [abstract no 12361]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998:85.
108. 108. Staszewski S, Morales-Ramirez J, Flanigan T, et al. A phase II, multicenter, randomized study to compare the antiretroviral activity and tolerability of efavirenz (EFV) + indinavir (IND), versus EFV + zidovudine (ZDV) + lamivudine (3TC), versus IDV + ZDV + 3TC at 24 weeks [abstract no 22336]. In: Conference record of the 12th World AIDS Conference. Geneva: Marathon Multimedia, 1998:330.